Oncology Research Editorial Office

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.081287 - 23 March 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.081286 - 23 March 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.081284 - 23 March 2026

Abstract This article has no abstract. More >

Wubin Zhao^#, Qi Wang^#, Jun Zhang^*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.076406 - 23 March 2026

Abstract Disulfidptosis is a newly identified form of regulated cell death (RCD) first described in 2023, representing a significant advance in understanding programmed cell death pathways. This unique cell death modality is characterized by abnormal intracellular accumulation of disulfide bonds and disruption of redox homeostasis, leading to cytoskeletal collapse without caspase activation. Disulfidptosis is primarily triggered by glucose deprivation in cells with high expression of solute carrier family 7 member 11 (SLC7A11). Under these conditions, insufficient NADPH supply prevents the effective reduction of accumulated cystine to cysteine, thereby inducing disulfide stress. Distinct from apoptosis, ferroptosis, cuproptosis,… More >

Xiaomeng Li^1,2, Xuejiao Li², Hongbo Wu^1,*, Rui Li^1,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.076176 - 23 March 2026

Abstract Lung cancer remains the leading cause of cancer-related mortality worldwide, primarily driven by metabolic reprogramming and immune evasion mechanisms within tumor cells. To adapt to the nutrient-deprived tumor microenvironment (TME), lung cancer cells undergo profound metabolic reprogramming, characterized by enhanced glycolysis (the Warburg effect), increased glutamine dependency (mediated by GLS1), and accelerated lipid synthesis (involving enzymes such as FASN). These metabolic alterations not only remodel the TME but also dampen antitumor immune responses by promoting immunosuppressive cell populations (e.g., Tregs and M2 macrophages) and inhibiting effector functions of CD8⁺ T cells and natural killer (NK) cells.… More >

Ye Ri Han^1,*, Sang Bong Lee^2,3,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.075923 - 23 March 2026

Abstract Radiopharmaceuticals deliver diagnostic or therapeutic radionuclides to disease sites with molecular precision. Over the past five years, clinical adoption has accelerated, led by U.S. Food and Drug Administration approvals of ¹⁷⁷Lu-DOTA-TATE and ¹⁷⁷Lu-PSMA-617 and their complementary Positron Emission Tomography agents (⁶⁸Ga-DOTA-TATE, ⁶⁸Ga-PSMA-11), which have established radiotheranostics as a pillar of oncology care. The new generation of agents couples optimized radionuclides (β⁻, α, and Auger emitters) to antibodies, peptides, and small-molecule vectors that improve tumor uptake, residence time, and clearance profiles, thereby enhancing efficacy and safety. Beyond neuroendocrine tumors and prostate cancer, radiotheranostic strategies are advancing for diverse malignancies… More >

Yiran Dong¹, Jingyue Wang¹, Jiayang Chen², Liang Mo², Yong You^1,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.075191 - 23 March 2026

Abstract Background: Lung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer, remains a leading cause of cancer-related mortality due to late diagnosis, metastasis, and therapy resistance. The aim of the study is to investigate the role of Kinetochore Scaffold 1 (KNL1) in promoting LUAD progression and its underlying molecular regulatory mechanisms. Methods: KNL1 mRNA expression levels across 33 cancer types were analyzed using bioinformatics analysis based on the TCGA database. Immunohistochemistry (IHC) was used to assess KNL1 expression in LUAD and normal tissues. Stable KNL1-knockdown and KNL1-overexpressing LUAD cell lines were established using lentiviral… More >

Jiaxi Li^#, Deepak Iyer^#, Siming Sui, Zheng Huang, Ryan Wai-Yan Sin, Abraham Tak-Ka Man, Wai-Lun Law, Chi-Chung Foo^*, Lui Ng^*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074981 - 23 March 2026

Abstract Objectives: Piwi-associated RNAs are small non-coding RNAs implicated in cancer, yet few have been characterized in colorectal cancer (CRC). This study aimed to identify a CRC-related piRNA and investigate its clinical relevance, biological function, and biomarker potential. Methods: Candidates were identified by reanalysis of small-RNA sequencing. piR-37524 was quantified by quantitative real-time polymerase chain reaction (qRT-PCR) in colorectal cancer tissues, matched adjacent non-tumor tissues, colorectal adenomas, liver metastases, and serum samples from patients and healthy controls. Clinicopathological correlations and diagnostic performance were evaluated. Functional assays included 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation, colony formation, and wound-healing migration… More >

Denisse A. Gutierrez^*, Elisa Robles-Escajeda, Jose A. Lopez-Saenz, Robert A. Kirken, Edgar A. Borrego, Ana P. Betancourt, Soumya Nair, Sourav Roy, Armando Varela-Ramirez, Renato J. Aguilera^*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074945 - 23 March 2026

Abstract Objectives: Drug resistance is the major determinant of chemotherapy failure, leading to relapse and tumor progression, demonstrating the urgent need for novel antineoplastic drugs. This study aimed to evaluate the anticancer potential of two novel pyrazole derivatives, P3C.1 and P3C.2, and to elucidate their mechanism of action in cancer cells. Methods: The cytotoxicity of the compounds was evaluated across 27 different cancer cell lines via a nuclear staining assay. Subsequent flow cytometric and biochemical analyses were performed to assess reactive oxygen species (ROS) generation, apoptosis induction, mitochondrial integrity, and cell cycle progression. Additional studies included… More >

Chang He^#, An Wang^#, Youbo Wang^#, Qinyun Ma^*, Xiaofeng Chen^*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074880 - 23 March 2026

Abstract Objectives: Combined chemotherapy and photothermal therapy (PTT) represents a promising approach for enhancing cancer treatment efficacy. This study aimed to develop arsenic trioxide (ATO) and poly(cyclopentadithiophene-alt-benzothiadiazole) (PCPDTBT)-loaded nanoparticles (ATO/PCPDTBT@NPs) to evaluate their synergistic efficacy in inhibiting lung cancer growth and metastasis. Methods: Nanovesicles were synthesized via a streamlined protocol and subjected to 808 nm NIR irradiation to assess their photothermal conversion capabilities. The therapeutic efficacy was evaluated in vitro using A549 lung carcinoma cells to assess apoptosis, invasion, and migration, and in vivo to monitor tumor volume reduction. Results: The nanoparticles exhibited excellent hemocompatibility and low cytotoxicity while More >